专利检索_ ..rRNA核酸内切酶专利检索_ ..rRNA核酸内切酶专利检索查询

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
1	Ribotoxin molecules derived from sarcin and other related fungal ribotoxins	US14774445	2014-03-03	US09603911B2	2017-03-28	Kurt R. Gehlsen; Timothy David Jones; Francis Joseph Carr; Arron Hearn
The present application relates to modified T cell epitopes derived from fungal ribotoxins, including a-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.
2	Ribotoxin molecules derived from sarcin and other related fungal ribotoxins	US15430906	2017-02-13	US09976131B2	2018-05-22	Kurt R. Gehlsen; Timothy David Jones; Francis Joseph Carr; Arron Hearn
The present application relates to modified T cell epitopes derived from fungal ribotoxins, including α-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.
3	RIBOTOXIN MOLECULES DERIVED FROM SARCIN AND OTHER RELATED FUNGAL RIBOTOXINS	US15430906	2017-02-13	US20170204387A1	2017-07-20	Kurt R. Gehlsen; Timothy David Jones; Francis Joseph Carr; Arron Hearn
The present application relates to modified T cell epitopes derived from fungal ribotoxins, including α-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.
4	RIBOTOXIN MOLECULES DERIVED FROM SARCIN AND OTHER RELATED FUNGAL RIBOTOXINS	US14774445	2014-03-03	US20160106819A1	2016-04-21	Kurt R. Gehlsen; Timothy David Jones; Francis Joseph Carr; Arron Hearn
The present application relates to modified T cell epitopes derived from fungal ribotoxins, including a-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.
5	サルシン及び他の関連する真菌リボトキシンに由来するリボトキシン分子	JP2016500564	2014-03-03	JP2016512251A	2016-04-25	カートアール．ゲールセン; ティモシーデイビッドジョーンズ; フランシスジョセフカー; アーロンハーン
本出願は、α−サルシン、クラビン、ギガンチン、マイトギリン、及びレストリクトシンを含む真菌リボトキシンに由来する修飾T細胞エピトープ、並びに1又は複数の修飾エピトープを含む修飾リボトキシン分子に関する。修飾リボトキシン分子は、野生型リボトキシンのようにタンパク質の合成を阻害するが、対応する野生型リボトキシンと比較して低減された免疫原性を呈する。別の態様は、目的の標的に結合するのに有効な標的分子に融合又は接合、或いは連結された修飾リボトキシンを含む融合タンパク質に関する。別の態様は、疾患又は状態の治療又は管理に対する修飾リボトキシン又は融合タンパク質の使用に関する。【選択図】図3A
6	サルシン及び他の関連する真菌リボトキシンに由来するリボトキシン分子	JP2016500564	2014-03-03	JP6203372B2	2017-09-27	ゲールセンカートアール.; ジョーンズティモシーデイビッド; カーフランシスジョセフ; ハーンアーロン

7	RIBOTOXIN MOLECULES DERIVED FROM SARCIN AND OTHER RELATED FUNGAL RIBOTOXINS	EP14775634	2014-03-03	EP2971038A4	2016-11-23	GEHLSEN KURT R; JONES TIMOTHY DAVID; CARR FRANCIS JOSEPH; HEARN ARRON
The present application relates to modified T cell epitopes derived from fungal ribotoxins, including a-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.
8	RIBOTOXIN MOLECULES DERIVED FROM SARCIN AND OTHER RELATED FUNGAL RIBOTOXINS	EP14775634.0	2014-03-03	EP2971038A1	2016-01-20	GEHLSEN, Kurt, R.; JONES, Timothy, David; CARR, Francis, Joseph; HEARN, Arron
The present application relates to modified T cell epitopes derived from fungal ribotoxins, including a-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.

该功能需要专业版企业版VIP权限，您可以：